高级搜索

共刺激分子B7-H3在人食管鳞癌中的表达及临床意义

曹娜娜, 王玲, 王珊, 单保恩

曹娜娜, 王玲, 王珊, 单保恩. 共刺激分子B7-H3在人食管鳞癌中的表达及临床意义[J]. 肿瘤防治研究, 2014, 41(12): 1300-1303. DOI: 10.3971/j.issn.1000-8578.2014.12.010
引用本文: 曹娜娜, 王玲, 王珊, 单保恩. 共刺激分子B7-H3在人食管鳞癌中的表达及临床意义[J]. 肿瘤防治研究, 2014, 41(12): 1300-1303. DOI: 10.3971/j.issn.1000-8578.2014.12.010
CAO Na'na, WANG Ling, WANG Shan, SHAN Baoen. Expression of Costimulatory Molecule B7-H3 in Human Esophageal Squamous Cell Carcinoma and Clinical Significance[J]. Cancer Research on Prevention and Treatment, 2014, 41(12): 1300-1303. DOI: 10.3971/j.issn.1000-8578.2014.12.010
Citation: CAO Na'na, WANG Ling, WANG Shan, SHAN Baoen. Expression of Costimulatory Molecule B7-H3 in Human Esophageal Squamous Cell Carcinoma and Clinical Significance[J]. Cancer Research on Prevention and Treatment, 2014, 41(12): 1300-1303. DOI: 10.3971/j.issn.1000-8578.2014.12.010

共刺激分子B7-H3在人食管鳞癌中的表达及临床意义

基金项目: 国家自然资金面上项目(81173611)
详细信息
    作者简介:

    曹娜娜(1987-),女,硕士在读,主要从事肿瘤分子诊断学研究

    通信作者:

    单保恩,E-mail:shanbaoen_1962@163.com

  • 中图分类号: R735.1;R730.231

Expression of Costimulatory Molecule B7-H3 in Human Esophageal Squamous Cell Carcinoma and Clinical Significance

  • 摘要: 目的 分析人食管鳞癌组织中B7-H3分子的表达与患者临床病理因素以及术后生存时间之间的关系。方法 采用免疫组织化学法检测82例人食管癌组织、对应癌旁正常食管组织及食管鳞状上皮不典型增生组织中B7-H3分子的表达以及CD8+T淋巴细胞的浸润程度。结果 食管癌组织中B7-H3 蛋白的阳性表达率为98.8%(81/82),而B7-H3在癌旁及鳞状上皮不典型增生组织中几乎不表达。B7-H3 的表达与患者年龄、肿瘤浸润深度及TNM分期相关,差异有统计学意义(P<0.05),与肿瘤组织中CD8+T淋巴细胞浸润程度呈负相关(P<0.05),与患者预后呈负相关(P<0.05)。结论 B7-H3在食管癌中过表达,和肿瘤的进展密切相关。食管癌中B7-H3分子的表达可能参与了抑制食管癌组织内CD8+T 细胞功能,促使肿瘤细胞逃避免疫监视,提示B7-H3在食管癌诊断、判断预后及靶向治疗中具有潜在的临床应用价值。

     

    Abstract: Objective To analyze the relationship of B7-H3 expression in human esophageal squamous cell carcinoma (ESCC) and clinicopathological parameters as well as overall survival in ESCC patients. Methods Immunohistochemical assay was applied to evaluate the expression of B7-H3 and the intensity of tumor infiltrating CD8+T lymphocytes in 82 cases of ESCC tissues, corresponding adjacent tissues and esophageal squamous atypical hyperplasia tissues. Results B7-H3 expression was found in 98.8% (81/82) of ESCC tissues, while it was almost negative in adjacent tissues and atypical hyperplasia tissues. The abnormal expression of B7-H3 was correlated with age, tumor grade and TNM stage (P<0.05). Meanwhile, B7-H3 expression was negatively correlated with the intensity of tumor infiltrating CD8+T lymphocytes and postoperative prognosis (P<0.05). Conclusion B7-H3 is overexpressed in ESCC tissues, which is closely correlated with tumor stage. Moreover, B7-H3 overexpression could reflect CD8+T cell infiltration and may help tumor cells avoid immune surveillance. Therefore, B7-H3 plays significant roles in diagnosis, targeted therapeutics and prognosis.

     

  • [1] Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. Int J Cancer, 2010, 12 7(12): 2893-917.
    [2] Hagymási K, Tulassay Z. Risk factors for esophageal cancer, and possible genetic background[J]. Orv Hetil, 2009, 150(9): 407-13.
    [3] Petroff MG, Perchellet A. B7 family molecules as regulators of the maternal immune system in pregnancy[J]. Am J Reprod Immunol, 20 10, 63(6): 506-19.
    [4] Xiong XJ, Yang M, Fang DM, et al. Expression of B7 costimulator in human malignant hematological cell lines and its effects on activation of human peripheral blood T lymphocyte[J]. Mian Yi Xue Za Zhi, 2009, 25(6): 621-4.[熊秀娟, 杨铭, 范冬梅, 等. B7在 血液病细胞系中的表达及对T淋巴细胞的免疫反应[J]. 免疫学 杂志, 2009, 25(6): 621-4.]
    [5] Loos M, Hedderich DM, Friess H, et al. B7-h3 and its role in antitumor immunity[J]. Clin Dev Immunol, 2010, 2010: 683875.
    [6] Chapoval AI, Ni J, Lau JS, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production[J]. Nat Immunol, 20 01, 2(3): 269-74.
    [7] Ling V, Wu PW, Spaulding V, et al. Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss[J]. Genomics, 20 03, 82(3): 365-77.
    [8] Sun M, Richards S, Prasad DV, et al. Characterization of mouse and human B7-H3 genes[J]. J Immunol, 2002, 168(12): 6294-7.
    [9] Tran CN, Thacker SG, Louie DM, et al. Interactions of T cells with fibroblast-like synoviocytes: role of the B7 family costimulatory ligand B7-H3[J]. J Immunol, 2008, 180(5): 2989-98.
    [10] Suh WK, Gajewska BU, Okada H, et al. The B7 family member B7-H3 preferentially down-regulates T helper type1-mediated immune responses[J]. Nat Immunol, 2003, 4(9): 899-906.
    [11] Prasad DV, Nguyen T, Li Z, et al. Murine B7-H3 is a negative regulator of T cells[J]. J Immunol, 2004, 173(4): 2500-6.
    [12] Xu YH, Zhang GB, Wang JM, et al. Effect of B7-H3 on growth of lewis lung carcinoma cell[J]. Zhong Liu Fang Zhi Yan Jiu, 2012, 39 (4): 376-80.[徐跃华, 张光波, 汪家敏, 等. B7-H3对小鼠Lewis 肺癌细胞生长的影响[J]. 肿瘤防治研究, 2012, 39(4): 376-80.]
    [13] Wu CP, Jiang JT, Tan M, et al. Relationship between costimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis[J]. World J Gastroenterol, 2006, 12(3): 45 7-9.
    [14] Sun Y, Wang Y, Zhao J, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer[J]. Lung Cancer, 2006, 53(2): 143-51.
    [15] Arigami T, Narita N, Mizuno R, et al. B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis[J]. Ann Surg, 2010, 252(6): 1044-51.
    [16] Roth TJ, Sheinin Y, Lohse CM, et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy[J]. Cancer Res, 2007, 67(16): 7893-900.
    [17] Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome[J]. Science, 2006, 313(5795): 1960-4.
    [18] Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer[J]. J Clin Oncol, 2011, 29(15): 1949-55.
计量
  • 文章访问数:  2530
  • HTML全文浏览量:  456
  • PDF下载量:  405
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-01-09
  • 修回日期:  2014-03-17
  • 刊出日期:  2014-12-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭